Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study.

Target Oncol · 2026 · PMC13222273 · PMID 42070217

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Building on this, PACIFIC-5 demonstrated that durvalumab improved median PFS versus the effect of a placebo (14.0 versus 6.5 months, P = 0.038) in cCRT and sCRT subgroups among Chinese patients, with a favorable trend toward improved OS, reinforcing its role as a key consolidation strategy for this population [ 9 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.